索拉非尼治疗原发性肝癌的不良反应分析  

Adverse reactions of using sorafenib in primary liver cancer

作　　者：闫敏[1] 潘跃银[1] 

机构地区：[1]安徽医科大学第一附属医院,安徽合肥230022

出　　处：《安徽医药》2010年第9期1066-1068,共3页Anhui Medical and Pharmaceutical Journal

基　　金：安徽省科技厅重点项目(No07020304102)

摘　　要：目的分析索拉非尼在国人中治疗原发性肝癌患者过程中出现的不良反应的特征。方法对在该科应用索拉非尼治疗原发性肝癌的30例患者的各种可能与应用索拉非尼有关的不良反应进行分级、记录与统计分析。结果观察到患者出现的与服用索拉非尼有关的不良反应主要为手足综合征、血压升高、脱发、腹泻、疲乏等。结论国人应用索拉非尼患者手足综合征、高血压、腹泻的发生率较高,亦可观察到骨髓抑制及肾功能损害,不良反应一般为轻中度,患者大多可以耐受,不需特殊处理。对于部分严重不良反应,予以停药或对症处理后均恢复正常。Aim To analyze the molecular target drug sorafenib treatment of primary liver cancer in patients with adverse events arising in the course of the characteristics.Methods Data of 30 cases of application of sorafenib treatment of primary liver cancer in patients which may be related to a variety of sorafenib-related adverse events were graded,recorded and statistically analyzed.Results The adverse events were mainly hand-foot syndrome,high blood pressure,hair loss,diarrhea,fatigue and so on.Conclusion Bone marrow suppression can also be observed and renal function impairment in patients with hand-foot syndrome,high blood pressure,and high incidence of diarrhea.Adverse reactions are generally mild to moderate,and patients are mostly tolerated,without special treatment.For some serious adverse reactions,it can return to normal through the interruption of treatment or symptomatic treatment.

关 键 词：索拉非尼 原发性肝癌 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]